Kallyope valuation, funding and investors

Kallyope works in neurological disease therapeutics discovery, based in New York, United States. Founded in 2015, it has about 54 employees.

Biotechnology New York Series D

VALUATION · TODAY

$236M −6% after Series D

Range $93.0M – $1.76B · Grade D

TODAY

+12 MO

$500M

$1.00B

$1.50B

$2.00B

$2.50B

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series A $44.0M

Series B $66.0M

Series C $112M

Series D $236M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY54 employees

−18%6m growth

−22%1y growth

−33%2y growth

100

150

Data from Jan 2021

TODAY

Predicted in 1 yr $223M −6% vs today

Predicted next raise $169M if a round comes

Winding-down probability 97%

Last round: Series D · $236M · Feb 2022
Valuation at last round: $1.30B
Headcount: 54 · down
Grade: D
Founded: 2015

How VCMC values companies →

Kallyope valuation today

VCMC values Kallyope at $236M today, with a range of $93.0M to $1.8B and a grade of D. The valuation starts from its last funding round, a Series D round in Feb 2022.

Valuation by date (147 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Kallyope: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2015	$5.25M	$1.91M – $14.4M	$5.51M (+5%)	before first round	–	unknown	D	0%
1 Feb 2015	$5.28M	$1.92M – $14.5M	$5.53M (+5%)	before first round	–	unknown	D	0%
1 Mar 2015	$5.29M	$1.93M – $14.5M	$5.55M (+5%)	before first round	–	unknown	D	0%
1 Apr 2015	$5.32M	$1.93M – $14.6M	$5.57M (+5%)	before first round	–	unknown	D	0%
1 May 2015	$5.34M	$1.94M – $14.7M	$5.59M (+5%)	before first round	–	unknown	D	0%
1 Jun 2015	$5.36M	$1.95M – $14.7M	$5.61M (+5%)	before first round	–	unknown	D	0%
1 Jul 2015	$5.38M	$1.96M – $14.8M	$5.64M (+5%)	before first round	–	unknown	D	0%
1 Aug 2015	$5.40M	$1.97M – $14.8M	$5.78M (+7%)	before first round	–	unknown	D	0%
1 Sep 2015	$5.42M	$1.97M – $14.9M	$5.94M (+10%)	before first round	–	unknown	D	0%
1 Oct 2015	$5.44M	$1.98M – $14.9M	$6.09M (+12%)	before first round	–	unknown	D	0%
1 Nov 2015	$5.46M	$1.99M – $15.0M	$6.26M (+15%)	before first round	–	unknown	D	0%
1 Dec 2015	$5.48M	$2.00M – $15.1M	$6.42M (+17%)	before first round	–	unknown	D	0%
11 Dec 2015	$245M	$161M – $670M	$440M (+80%)	after a round	–	unknown	C	0%
1 Jan 2016	$253M	$161M – $670M	$440M (+74%)	after a round	–	unknown	C	0%
1 Feb 2016	$266M	$161M – $670M	$440M (+65%)	after a round	–	unknown	C	0%
1 Mar 2016	$279M	$161M – $670M	$440M (+58%)	after a round	–	unknown	C	0%
1 Apr 2016	$293M	$161M – $670M	$440M (+50%)	after a round	–	unknown	C	0%
1 May 2016	$308M	$161M – $670M	$440M (+43%)	after a round	–	unknown	C	0%
1 Jun 2016	$323M	$161M – $670M	$440M (+36%)	after a round	–	unknown	C	0%
1 Jul 2016	$339M	$161M – $670M	$440M (+30%)	after a round	–	unknown	C	0%
1 Aug 2016	$357M	$161M – $670M	$440M (+23%)	after a round	–	unknown	C	0%
1 Sep 2016	$375M	$161M – $670M	$440M (+17%)	after a round	–	unknown	C	0%
1 Oct 2016	$394M	$161M – $670M	$440M (+12%)	after a round	–	unknown	C	0%
1 Nov 2016	$414M	$161M – $670M	$440M (+6%)	after a round	–	unknown	C	0%
1 Dec 2016	$434M	$161M – $670M	$440M (+1%)	after a round	–	unknown	C	0%
1 Jan 2017	$440M	$155M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Feb 2017	$440M	$147M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Mar 2017	$440M	$140M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Apr 2017	$440M	$133M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 May 2017	$440M	$127M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Jun 2017	$440M	$121M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Jul 2017	$440M	$115M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Aug 2017	$440M	$109M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Sep 2017	$440M	$104M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Oct 2017	$440M	$98.8M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Nov 2017	$440M	$93.9M – $670M	$440M (0%)	after a round	–	unknown	C	0%
1 Dec 2017	$440M	$89.4M – $670M	$440M (0%)	after a round	–	unknown	D	0%
1 Jan 2018	$440M	$84.9M – $670M	$440M (0%)	after a round	–	unknown	D	0%
1 Feb 2018	$440M	$80.7M – $670M	$440M (0%)	after a round	–	unknown	D	0%
23 Feb 2018	$468M	$329M – $994M	$701M (+50%)	after a round	–	unknown	B	0%
1 Mar 2018	$471M	$329M – $994M	$701M (+49%)	after a round	–	unknown	B	0%
1 Apr 2018	$487M	$329M – $994M	$701M (+44%)	after a round	–	unknown	B	0%
1 May 2018	$504M	$329M – $994M	$701M (+39%)	after a round	–	unknown	B	0%
1 Jun 2018	$521M	$329M – $994M	$701M (+34%)	after a round	–	unknown	B	0%
1 Jul 2018	$539M	$329M – $994M	$701M (+30%)	after a round	–	unknown	B	0%
1 Aug 2018	$558M	$329M – $994M	$701M (+26%)	after a round	–	unknown	B	0%
1 Sep 2018	$577M	$329M – $994M	$701M (+21%)	after a round	–	unknown	B	0%
1 Oct 2018	$597M	$329M – $994M	$701M (+17%)	after a round	–	unknown	B	0%
1 Nov 2018	$618M	$329M – $994M	$701M (+13%)	after a round	–	unknown	B	0%
1 Dec 2018	$639M	$329M – $994M	$701M (+10%)	after a round	–	unknown	B	0%
1 Jan 2019	$661M	$329M – $994M	$701M (+6%)	after a round	–	unknown	B	0%
1 Feb 2019	$684M	$329M – $994M	$701M (+2%)	after a round	–	unknown	B	0%
1 Mar 2019	$701M	$326M – $994M	$701M (0%)	after a round	–	unknown	B	0%
1 Apr 2019	$701M	$312M – $994M	$701M (0%)	after a round	–	unknown	B	0%
1 May 2019	$701M	$299M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Jun 2019	$701M	$286M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Jul 2019	$701M	$274M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Aug 2019	$701M	$262M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Sep 2019	$701M	$251M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Oct 2019	$701M	$240M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Nov 2019	$701M	$230M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Dec 2019	$701M	$220M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Jan 2020	$701M	$211M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Feb 2020	$701M	$202M – $994M	$701M (0%)	after a round	–	unknown	C	0%
1 Mar 2020	$701M	$178M – $994M	$701M (0%)	after a round	–	unknown	C	0%
26 Mar 2020	$963M	$678M – $1.8B	$1.3B (+30%)	after a round	–	unknown	B	0%
1 Apr 2020	$967M	$678M – $1.8B	$1.3B (+29%)	after a round	–	unknown	B	0%
1 May 2020	$988M	$678M – $1.8B	$1.3B (+27%)	after a round	–	unknown	B	0%
1 Jun 2020	$1.0B	$678M – $1.8B	$1.3B (+24%)	after a round	–	unknown	B	0%
1 Jul 2020	$1.0B	$678M – $1.8B	$1.3B (+21%)	after a round	–	unknown	B	0%
1 Aug 2020	$1.1B	$678M – $1.8B	$1.3B (+18%)	after a round	–	unknown	B	0%
1 Sep 2020	$1.1B	$678M – $1.8B	$1.3B (+16%)	after a round	–	unknown	B	0%
1 Oct 2020	$1.1B	$678M – $1.8B	$1.3B (+13%)	after a round	–	unknown	B	0%
1 Nov 2020	$1.1B	$678M – $1.8B	$1.3B (+11%)	after a round	–	unknown	B	0%
1 Dec 2020	$1.2B	$678M – $1.8B	$1.3B (+9%)	after a round	–	unknown	B	0%
1 Jan 2021	$1.2B	$678M – $1.8B	$1.3B (+6%)	after a round	63	unknown	B	0%
1 Feb 2021	$1.2B	$678M – $1.8B	$1.3B (+4%)	after a round	63	unknown	B	0%
1 Mar 2021	$1.2B	$678M – $1.8B	$1.3B (+2%)	after a round	63	unknown	B	0%
1 Apr 2021	$1.3B	$671M – $1.8B	$1.3B (0%)	after a round	63	flat	B	0%
1 May 2021	$1.3B	$642M – $1.8B	$1.3B (0%)	after a round	63	flat	B	0%
1 Jun 2021	$1.3B	$612M – $1.8B	$1.3B (0%)	after a round	63	flat	B	0%
1 Jul 2021	$1.3B	$586M – $1.8B	$1.3B (0%)	after a round	63	flat	B	0%
1 Aug 2021	$1.3B	$559M – $1.8B	$1.3B (0%)	after a round	63	flat	B	0%
1 Sep 2021	$1.3B	$534M – $1.8B	$1.3B (0%)	after a round	63	flat	C	0%
1 Oct 2021	$1.3B	$510M – $1.8B	$1.3B (0%)	after a round	63	flat	C	0%
1 Nov 2021	$1.3B	$487M – $1.8B	$1.3B (0%)	after a round	63	flat	C	0%
1 Dec 2021	$1.3B	$466M – $1.8B	$1.3B (0%)	after a round	63	flat	C	0%
1 Jan 2022	$1.3B	$612M – $1.8B	$1.3B (0%)	after a round	83	up	B	0%
1 Feb 2022	$1.3B	$605M – $1.8B	$1.3B (0%)	after a round	83	up	B	0%
16 Feb 2022	$1.3B	$1.1B – $1.9B	$1.7B (+30%)	after a round	83	up	A	0%
1 Mar 2022	$1.3B	$1.1B – $1.9B	$1.7B (+29%)	after a round	83	up	A	0%
1 Apr 2022	$1.3B	$1.1B – $1.9B	$1.7B (+26%)	after a round	83	up	A	0%
1 May 2022	$1.4B	$1.1B – $1.9B	$1.7B (+23%)	after a round	83	up	A	0%
1 Jun 2022	$1.4B	$1.1B – $1.9B	$1.7B (+20%)	after a round	83	up	A	0%
1 Jul 2022	$1.4B	$1.1B – $1.9B	$1.7B (+18%)	after a round	83	up	A	0%
1 Aug 2022	$1.5B	$1.1B – $1.9B	$1.7B (+15%)	after a round	83	up	A	0%
1 Sep 2022	$1.5B	$1.1B – $1.9B	$1.7B (+13%)	after a round	83	up	A	0%
1 Oct 2022	$1.5B	$1.1B – $1.9B	$1.7B (+10%)	after a round	83	up	A	0%
1 Nov 2022	$1.6B	$1.1B – $1.9B	$1.7B (+8%)	after a round	83	unknown	A	0%
1 Dec 2022	$1.6B	$1.1B – $1.9B	$1.7B (+6%)	after a round	83	unknown	A	0%
1 Jan 2023	$1.6B	$1.1B – $1.9B	$1.7B (+3%)	after a round	83	unknown	A	0%
1 Feb 2023	$1.7B	$1.1B – $1.9B	$1.7B (+1%)	after a round	83	unknown	A	0%
1 Mar 2023	$1.7B	$1.1B – $1.9B	$1.7B (0%)	after a round	83	unknown	A	0%
1 Apr 2023	$1.7B	$1.1B – $1.9B	$1.7B (0%)	after a round	83	unknown	B	0%
1 May 2023	$1.8B	$1.1B – $2.0B	$1.8B (0%)	after a round	99	up	B	0%
1 Jun 2023	$1.8B	$1.1B – $2.0B	$1.8B (0%)	after a round	99	up	B	0%
1 Jul 2023	$1.8B	$1.1B – $2.0B	$1.8B (0%)	after a round	99	up	B	0%
1 Aug 2023	$1.8B	$896M – $2.0B	$1.8B (0%)	after a round	99	unknown	B	0%
1 Sep 2023	$1.8B	$858M – $2.0B	$1.8B (0%)	after a round	99	unknown	B	0%
1 Oct 2023	$1.8B	$1.1B – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Nov 2023	$1.8B	$1.1B – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Dec 2023	$1.8B	$1.1B – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Jan 2024	$1.8B	$1.1B – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Feb 2024	$1.8B	$1.1B – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Mar 2024	$1.8B	$953M – $2.1B	$1.8B (0%)	after a round	110	up	B	0%
1 Apr 2024	$1.8B	$935M – $2.1B	$1.8B (-1%)	after a round	110	up	B	0%
1 May 2024	$1.8B	$918M – $2.1B	$1.8B (-1%)	after a round	110	up	B	0%
1 Jun 2024	$1.8B	$900M – $2.1B	$1.8B (-2%)	after a round	110	up	B	0%
1 Jul 2024	$1.2B	$497M – $1.9B	$884M (-24%)	after a round	84	down	C	57%
1 Aug 2024	$854M	$469M – $1.8B	$551M (-36%)	after a round	81	down	C	97%
1 Sep 2024	$833M	$445M – $1.8B	$533M (-36%)	after a round	81	down	C	97%
1 Oct 2024	$814M	$424M – $1.8B	$516M (-37%)	after a round	81	down	C	97%
1 Nov 2024	$778M	$395M – $1.8B	$489M (-37%)	after a round	74	down	C	97%
1 Dec 2024	$578M	$376M – $1.3B	$334M (-42%)	after a round	74	shrinking	C	97%
1 Jan 2025	$556M	$357M – $1.3B	$320M (-43%)	after a round	74	shrinking	C	97%
1 Feb 2025	$536M	$339M – $1.3B	$307M (-43%)	after a round	74	shrinking	C	97%
1 Mar 2025	$485M	$324M – $1.0B	$282M (-42%)	after a round	74	shrinking	B	97%
1 Apr 2025	$465M	$308M – $1.0B	$270M (-42%)	after a round	74	shrinking	B	97%
1 May 2025	$446M	$293M – $993M	$259M (-42%)	after a round	74	shrinking	C	97%
1 Jun 2025	$428M	$279M – $973M	$248M (-42%)	after a round	74	shrinking	C	97%
1 Jul 2025	$411M	$265M – $953M	$238M (-42%)	after a round	74	shrinking	C	97%
1 Aug 2025	$389M	$249M – $922M	$225M (-42%)	after a round	70	shrinking	C	97%
1 Sep 2025	$373M	$237M – $903M	$216M (-42%)	after a round	70	shrinking	C	97%
1 Oct 2025	$545M	$225M – $1.9B	$349M (-36%)	after a round	69	down	D	89%
1 Nov 2025	$504M	$213M – $1.9B	$318M (-37%)	after a round	68	down	D	93%
1 Dec 2025	$489M	$203M – $1.9B	$307M (-37%)	after a round	68	down	D	93%
1 Jan 2026	$474M	$193M – $1.8B	$302M (-36%)	after a round	68	down	D	93%
1 Feb 2026	$503M	$183M – $1.8B	$340M (-33%)	after a round	68	down	D	85%
1 Mar 2026	$499M	$174M – $1.8B	$376M (-25%)	after a round	66	down	D	79%
1 Apr 2026	$529M	$165M – $1.8B	$414M (-22%)	after a round	66	down	D	72%
1 May 2026	$556M	$157M – $1.8B	$451M (-19%)	after a round	65	down	D	67%
1 Jun 2026	$585M	$149M – $1.8B	$489M (-16%)	after a round	65	flat	D	61%
1 Jul 2026	$611M	$141M – $1.7B	$524M (-14%)	after a round	64	flat	D	56%
1 Aug 2026	$638M	$134M – $1.7B	$560M (-12%)	after a round	64	flat	D	52%
1 Sep 2026	$664M	$127M – $1.7B	$594M (-11%)	after a round	64	flat	D	48%
1 Oct 2026	$293M	$117M – $1.8B	$268M (-9%)	after a round	54	down	D	97%
24 Oct 2026	$236M	$93.0M – $1.8B	$223M (-6%)	after a round	54	down	D	97%

Key facts about Kallyope

Founded: 2015
Headquarters: New York, United States
Employees: about 54 -22% in a year
Total raised: $458M
Funding rounds: 4
Last round: Series D Feb 2022

Kallyope was founded in 2015 by Charles Zuker, Richard Axel and Tom Maniatis.

Kallyope funding history

Kallyope has 4 funding rounds on record, from Dec 2015 to Feb 2022, $458M in total. The latest disclosed valuation is $1.30B post-money (Series D, Feb 2022).

Series D 15 Feb 2022
Led by Mubadala, The Column Group; with Alexandria Venture Investments, Breakthrough Energy, Casdin Capital, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, Two Sigma Ventures, StepStone Group, DNS Capital, Hartford Healthcare Endowment, Parkwood LLC, Tao Capital.
Sources: finsmes.com, biospace.com, pharmaceutical-technology.com and 2 more
$236M
$1.30B post-money
Series C 25 Mar 2020
With The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments, Casdin Capital, Greenspring Associates.
Sources: finsmes.com, prnewswire.com, alleywatch.com
$112M
Series B 22 Feb 2018
Led by Lux Capital; with The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital, Two Sigma Ventures.
Sources: prnewswire.com, biospace.com, healio.com and 1 more
$66M
Series A 10 Dec 2015
Led by Lux Capital; with Polaris Partners, The Column Group, Illumina Ventures, Alexandria Venture Investments. Individuals: Tony Evnin.
Sources: prnewswire.com, fiercebiotech.com, biopharmadive.com and 1 more
$44M

Kallyope investors

16 investors have backed Kallyope; Lux Capital, The Column Group and Mubadala led at least one round.

Lux Capital lead, 4 rounds
Mubadala lead
Alexandria Venture Investments 4 rounds
Euclidean Capital 3 rounds
Two Sigma Ventures 3 rounds
Breakthrough Energy
Greenspring Associates
Hartford Healthcare Endowment
Parkwood LLC
StepStone Group

What Kallyope does

Kallyope works in biotechnology, with 13 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.

Kallyope Inc. is an American biotechnology company engaged in the development of medicines for neurological and metabolic diseases. The company utilizes a technology platform that integrates single-cell transcriptional sequencing, pathway circuit mapping, optogenetics, chemogenetics, human genetics, and organoid technologies to advance drug discovery and development. Kallyope also conducts clinical research and development in areas such as metabolism, immunology and inflammation, and central nervous system disorders.

Description from Veridion's company data.

Products and services

Neurological Disease Therapeutics Discovery
Metabolic Disease Therapeutics Discovery
Immunology and Inflammation Therapeutics Discovery
Central Nervous System Therapeutics Development
Single-Cell Genomics Platform Development
Pathway Circuit Mapping Platform Development
Optogenetics and Chemogenetics Platform Development
Human Genetics Platform Development
Mouse and Human Organoid Platform Development
Small Molecule and Peptide Drug Development
Therapeutics Clinical Development
Therapeutics Regulatory Approval
Therapeutics Commercialization

Markets

Healthcare
Biotechnology
Pharmaceuticals

Technology

Single-Cell Transcriptional Sequencing
Pathway Circuit Mapping
Optogenetics
Chemogenetics
Proprietary Validated Human Genetics
Mouse and Human Organoids
Small Molecules and Peptides Capabilities

Business model

Business-to-Business
Manufacturing

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about Kallyope

What is Kallyope worth?

Valuation $236M (range $93.0M to $1.8B), as of 24 Oct 2026. The last disclosed valuation was $1.30B (Series D, Feb 2022).

Has Kallyope raised money?

Kallyope has 4 funding rounds on record, from Dec 2015 to Feb 2022, $458M in total. The latest disclosed valuation is $1.30B post-money (Series D, Feb 2022).

Who has invested in Kallyope?

Lux Capital, The Column Group, Mubadala, Alexandria Venture Investments, Illumina Ventures and Polaris Partners, and 10 more. Lead investors include Lux Capital, The Column Group and Mubadala.

How many people work at Kallyope?

About 54, down 22% over the last year. Headcount rose from 63 in Jan 2021 to 110 in Oct 2023, then fell to 54 in Sep 2026.

What does Kallyope do?

Kallyope works in biotechnology, with 13 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are neurological disease therapeutics discovery, metabolic disease therapeutics discovery and immunology and inflammation therapeutics discovery.

When was Kallyope founded, and where is it based?

Kallyope was founded in 2015 and is based in New York, United States. It has about 54 employees, down 22% over the last year.

How we value companies Report an issue